title: [Salvage therapy for severe aplastic anemia after allogenenic hematopoietic cell transplant].
abstract: OBJECTIVE
  To probe a practical salvage strategy for relapse or failure patients with severe aplastic anemia (SAA) after allogenenic hematopoietic cell transplant (allo-HSCT).
  
  
  METHODS
  The clinical characteristics and initial treatments of allo-HSCT, and the responses of a novel salvage therapy of cyclosporine alternately combined with levamisole (CsA & LMS regimen) plus danazol (DNZ) in 2 patients were reviewed and evaluated.
  
  
  RESULTS
  (1) Patient 1 achieved partial response (PR) at 3 months and complete response (CR) at 6 months after CsA & LMS regimen, respectively; Patient 2 also achieved PR 3 months and nearly CR at 6 months after the salvage therapy, respectively. (2) Increased numbers of T regulatory cells and colony forming unit-erythroid, burst-forming unit-erythroid, colony forming unit-granulocytes/macrophages after CsA & LMS regimen in both patients were observed.
  
  
  CONCLUSIONS
  This was the first report of successful salvage by a novel strategy of CsA & LMS regimen for relapse or failure patients with SAA after allo-HSCT.
authors.affiliation: Institute of Hematology & Hospital of Blood Diseases, CAMS & PUMC, Tianjin 300020, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Institute of Hematology & Hospital of Blood Diseases, CAMS & PUMC, Tianjin 300020, China.
authors.forename: Xingxin
authors.initials: X
authors.lastname: Li
authors.affiliation: Institute of Hematology & Hospital of Blood Diseases, CAMS & PUMC, Tianjin 300020, China.
authors.forename: Yingqi
authors.initials: Y
authors.lastname: Shao
authors.affiliation: Institute of Hematology & Hospital of Blood Diseases, CAMS & PUMC, Tianjin 300020, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Shi
authors.affiliation: Institute of Hematology & Hospital of Blood Diseases, CAMS & PUMC, Tianjin 300020, China.
authors.forename: Meili
authors.initials: M
authors.lastname: Ge
authors.affiliation: Institute of Hematology & Hospital of Blood Diseases, CAMS & PUMC, Tianjin 300020, China.
authors.forename: Zhendong
authors.initials: Z
authors.lastname: Huang
authors.affiliation: Institute of Hematology & Hospital of Blood Diseases, CAMS & PUMC, Tianjin 300020, China.
authors.forename: Neng
authors.initials: N
authors.lastname: Nie
authors.affiliation: Institute of Hematology & Hospital of Blood Diseases, CAMS & PUMC, Tianjin 300020, China.
authors.forename: Jinbo
authors.initials: J
authors.lastname: Huang
authors.affiliation: Institute of Hematology & Hospital of Blood Diseases, CAMS & PUMC, Tianjin 300020, China.
authors.forename: Yizhou
authors.initials: Y
authors.lastname: Zheng
mesh_terms: D000741:Anemia, Aplastic / Q000628:therapy*; D016572:Cyclosporine / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D012008:Recurrence; D016879:Salvage Therapy
chemical_list: D016572:Cyclosporine